Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism
- 1 December 2020
- journal article
- research article
- Published by Elsevier BV in Endocrine Practice
- Vol. 26 (12), 1416-1424
- https://doi.org/10.4158/ep-2020-0277
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Acute and chronic regulation of aldosterone productionMolecular and Cellular Endocrinology, 2012
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeuticsMolecular and Cellular Endocrinology, 2012
- Factors Affecting the Aldosterone/Renin RatioHormone and Metabolic Research, 2011
- A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronismJournal of Hypertension, 2011
- Cardiovascular Outcomes in Patients With Primary Aldosteronism After TreatmentArchives of Internal Medicine, 2008
- Long-term Renal Outcomes in Patients With Primary AldosteronismJAMA, 2006
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsThe New England Journal of Medicine, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999
- CANRENONE—THE PRINCIPAL ACTIVE METABOLITE OF SPIRONOLACTONE?British Journal of Clinical Pharmacology, 1976
- Potassium-Aldosterone-Renin InterrelationshipsJournal of Clinical Endocrinology & Metabolism, 1975